Literature DB >> 18020718

Modeling population heterogeneity in appearance- and performance-enhancing drug (APED) use: applications of mixture modeling in 400 regular APED users.

Thomas Hildebrandt1, James W Langenbucher, Sasha J Carr, Pilar Sanjuan.   

Abstract

Appearance- and performance-enhancing drugs (APEDs) constitute a wide range of substances, including anabolic-androgenic steroids, nonsteroidal anabolics, and licit and illicit ergo/thermogenics. A great deal of heterogeneity exists in APED use patterns among weight-lifting men, and, consequently, little is known about how these patterns are related to side effect profiles or risk potential. In the current study, a sample of 400 adult men who were regular APED users completed an interactive Web-based instrument detailing information about APED use, side effects, and related indicators of risk. To explore the heterogeneity of APED use patterns, the authors subjected data on use patterns to (a) latent class analysis (LCA), (b) latent trait analysis (LTA), and (c) factor mixture analysis to determine the best model of APED use. Results indicated that a 4-class factor mixture model provided a better fit than LCA and LTA models. The authors also found that severity and latent class were uniquely associated with negative outcomes. Each of the 4 classes was associated with unique side effects, motivations, and participant use patterns. Implications for identifying pathological forms of APED use are discussed. (c) 2007 APA

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18020718     DOI: 10.1037/0021-843X.116.4.717

Source DB:  PubMed          Journal:  J Abnorm Psychol        ISSN: 0021-843X


  29 in total

1.  Heterogeneity moderates treatment response among patients with binge eating disorder.

Authors:  Robyn Sysko; Tom Hildebrandt; G Terence Wilson; Denise E Wilfley; W Stewart Agras
Journal:  J Consult Clin Psychol       Date:  2010-10

2.  The impact of gender on the assessment of body checking behavior.

Authors:  Lauren Alfano; Tom Hildebrandt; Katie Bannon; Catherine Walker; Kate E Walton
Journal:  Body Image       Date:  2010-11-18

3.  Development and validation of the appearance and performance enhancing drug use schedule.

Authors:  Tom Hildebrandt; James W Langenbucher; Justine Karmin Lai; Katharine L Loeb; Eric Hollander
Journal:  Addict Behav       Date:  2011-05-11       Impact factor: 3.913

4.  Concerns related to eating, weight, and shape: typologies and transitions in men during the college years.

Authors:  Angela S Cain; Amee J Epler; Douglas Steinley; Kenneth J Sher
Journal:  Int J Eat Disord       Date:  2011-07-08       Impact factor: 4.861

5.  Using Factor Mixture Models to Evaluate the Type A/B Classification of Alcohol Use Disorders in a Heterogeneous Treatment Sample.

Authors:  Tom Hildebrandt; Elizabeth E Epstein; Robyn Sysko; Donald A Bux
Journal:  Alcohol Clin Exp Res       Date:  2017-03-30       Impact factor: 3.455

6.  The influence of age of onset and acute anabolic steroid exposure on cognitive performance, impulsivity, and aggression in men.

Authors:  Tom Hildebrandt; James W Langenbucher; Adrianne Flores; Seth Harty; Heather A Berlin; Heather Berlin
Journal:  Psychol Addict Behav       Date:  2014-05-19

7.  Psychosocial correlates of gap time to anabolic-androgenic steroid use.

Authors:  Patrycja Klimek; Tom Hildebrandt
Journal:  Int J Eat Disord       Date:  2018-03-15       Impact factor: 4.861

8.  Mood Symptoms in Steroid Users: The Unexamined Role of Concurrent Stimulant Use.

Authors:  Pilar M Sanjuan; James L Langenbucher; Tom Hildebrandt
Journal:  J Subst Use       Date:  2015-09-18

9.  Evaluating new severity dimensions in the DSM-5 for bulimic syndromes using mixture modeling.

Authors:  Pamela K Keel; Ross D Crosby; Thomas B Hildebrandt; Alissa A Haedt-Matt; Julie A Gravener
Journal:  Int J Eat Disord       Date:  2012-08-13       Impact factor: 4.861

10.  Self-Perceived Weight and Anabolic Steroid Misuse Among US Adolescent Boys.

Authors:  Jonathan D Jampel; Stuart B Murray; Scott Griffiths; Aaron J Blashill
Journal:  J Adolesc Health       Date:  2015-11-17       Impact factor: 5.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.